Cardurion Pharmaceuticals, Inc., a biotechnology company focused on discovery and development of next-generation therapeutics for heart failure and cardiovascular disease, has received a $300 million investment from Bain Capital Life Sciences and Bain Capital Private Equity.

This investment makes Bain Capital the third company along with Takeda Pharmaceuticals and Polaris Partners in supporting Cardurion. The investment will help Carudrion scale its team and create its industry-leading program.

“We could not be more excited to welcome Bain Capital as investors in this
transformational milestone for Cardurion,” added Peter Lawrence, CEO of Cardurion. “We have a shared vision to continue to build a world-class cardiovascular company pursuing treatments for a broad range of debilitating diseases. This funding will allow us to advance our first-in-class PDE9 inhibitor into a major Phase 2 trial in heart failure and to support the initiation of first-in-human studies with our CaMKII inhibitor program in several cardiovascular indications.”